Serotonin Uptake Inhibitors
-
Subject Areas on Research
-
24- and 36-week outcomes for the Child/Adolescent Anxiety Multimodal Study (CAMS).
-
A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder.
-
A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients.
-
A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).
-
A multi-site randomized clinical trial to reduce suicidal ideation in suicidal adult outpatients with Major Depressive Disorder: Development of a methodology to enhance safety.
-
A pilot randomized controlled trial with paroxetine for subthreshold PTSD in Operation Enduring Freedom/Operation Iraqi Freedom era veterans.
-
A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder.
-
A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia.
-
A pooled analysis of gender and trauma-type effects on responsiveness to treatment of PTSD with venlafaxine extended release or placebo.
-
A possible role of recurrent major depression in risk of fracture.
-
A randomized controlled trial of paroxetine for noncardiac chest pain.
-
A randomized, controlled, trial of controlled release paroxetine in fibromyalgia.
-
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.
-
A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil.
-
A systematic review of newer pharmacotherapies for depression in adults: evidence report summary.
-
Acute 5-HT reuptake blockade potentiates human amygdala reactivity.
-
Acute time to response in the Treatment for Adolescents with Depression Study (TADS).
-
Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.
-
Adjuvant trazodone in the treatment of alcoholism: an open study.
-
Adolescent male rats are less sensitive than adults to the anxiogenic and serotonin-releasing effects of fenfluramine.
-
Advances in Pharmacotherapy of Late-Life Depression.
-
Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults.
-
Alterations in serotonin transporter expression in brain regions of rats exposed neonatally to chlorpyrifos.
-
Amitifadine, a triple reuptake inhibitor, reduces self-administration of the opiate remifentanil in rats.
-
An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression.
-
An exploratory analysis of the impact of family functioning on treatment for depression in adolescents.
-
Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast.
-
Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial.
-
Antidepressant treatment and worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study.
-
Antidepressant use, depression, and survival in patients with heart failure.
-
Antidepressants in pregnancy: a review of commonly prescribed medications.
-
Anxiety Disorders in Caucasian and African American Children: A Comparison of Clinical Characteristics, Treatment Process Variables, and Treatment Outcomes.
-
Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis.
-
Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report.
-
Assessment of safety and long-term outcomes of initial treatment with placebo in TADS.
-
Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation.
-
Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs.
-
Atypical neuroleptic malignant syndrome caused by clozapine and venlafaxine: early brief treatment with dantrolene.
-
Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder.
-
Benefits of child-focused anxiety treatments for parents and family functioning.
-
Biological therapies for posttraumatic stress disorder: an overview.
-
Botulinum toxin treatment of social anxiety disorder with hyperhidrosis: a placebo-controlled double-blind trial.
-
Bursts and the efficacy of selective serotonin reuptake inhibitors.
-
Cardiology Patient Page. Depression after heart attack: why should I be concerned about depression after a heart attack?
-
Child/Adolescent anxiety multimodal study: evaluating safety.
-
Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release.
-
Chronic SSRI treatment exacerbates serotonin deficiency in humanized Tph2 mutant mice.
-
Citalopram and quality of life in lung transplant recipients.
-
Clinical evaluation of the efficacy and safety of tandospirone versus sertraline monotherapy for social anxiety disorder: a randomized open-label trial.
-
Clinical experience using appetite suppressants and SSRIs.
-
Clinical experience with substance P receptor (NK1) antagonists in depression.
-
Clinical trial evidence for treatment of depression in heart failure.
-
Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial.
-
Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety.
-
Cognitive measures of adolescent depression: unique or unitary constructs?
-
Combination pharmacotherapy: a mixture of small doses of naltrexone, fluoxetine, and a thyrotropin-releasing hormone analogue reduces alcohol intake in three strains of alcohol-preferring rats.
-
Comparative efficacy of cognitive behavioral therapy, fluoxetine, and their combination in depressed adolescents: initial lessons from the treatment for adolescents with depression study.
-
Consensus statement on depression, anxiety, and cardiovascular disease.
-
Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety.
-
Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety.
-
Consideration of allosterism and interacting proteins in the physiological functions of the serotonin transporter.
-
Continued cognitive-behavior therapy versus sertraline for children and adolescents with obsessive-compulsive disorder that were non-responders to cognitive-behavior therapy: a randomized controlled trial.
-
Cost-effectiveness of treatments for adolescent depression: results from TADS.
-
Davidson Trauma Scale (DTS): normative scores in the general population and effect sizes in placebo-controlled SSRI trials.
-
Defining treatment response and remission in child anxiety: signal detection analysis using the pediatric anxiety rating scale.
-
Depression and insomnia in women.
-
Depression and ischemic heart disease: what have we learned from clinical trials?
-
Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study.
-
Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment.
-
Depression in Maltreated Children and Adolescents.
-
Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors.
-
Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause.
-
Difficult behaviors in long-term care patients with dementia.
-
Drugs of the psychopharmacological revolution in clinical psychiatry.
-
Early pharmacological treatment of autism: a rationale for developmental treatment.
-
Easing the burden of social anxiety disorder.
-
Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.
-
Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial.
-
Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease.
-
Effect of selective serotonin reuptake inhibitors on the risk of fracture.
-
Effects of Exercise and Sertraline on Measures of Coronary Heart Disease Risk in Patients With Major Depression: Results From the SMILE-II Randomized Clinical Trial.
-
Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction.
-
Effects of coping skills training and sertraline in patients with non-cardiac chest pain: a randomized controlled study.
-
Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics.
-
Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial.
-
Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials.
-
Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis.
-
Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies.
-
Efficacy of newer medications for treating depression in primary care patients.
-
Escitalopram in specific phobia: results of a placebo-controlled pilot trial.
-
Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.
-
Escitalopram treatment of trichotillomania.
-
Establishing the neurobiologic basis of treatment in children and adolescents with generalized anxiety disorder.
-
Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder.
-
Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression.
-
Evidence-based clinical practice guidelines for managing depression in persons living with HIV.
-
Examining Parental Medication Adherence as a Predictor of Child Medication Adherence in Pediatric Anxiety Disorders.
-
Extreme thinking in clinically depressed adolescents: Results from the Treatment for Adolescents with Depression Study (TADS).
-
Factor structure and psychometric properties of the Children's Negative Cognitive Error Questionnaire with a clinically depressed adolescent sample.
-
Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders.
-
Fluoxetine Maintains a State of Heightened Responsiveness to Motor Training Early After Stroke in a Mouse Model.
-
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
-
Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia.
-
Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group.
-
Fluvoxamine in civilians with posttraumatic stress disorder.
-
Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder.
-
Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study.
-
Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.
-
Folate metabolism genes, dietary folate and response to antidepressant medications in late-life depression.
-
Functional connectivity predictors of acute depression treatment outcome.
-
Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS).
-
Generalized anxiety disorder: acute and chronic treatment.
-
Generalized social anxiety disorder and avoidant personality disorder: structural analysis and treatment outcome.
-
Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients.
-
Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.
-
Goldenhar syndrome associated with prenatal maternal Fluoxetine ingestion: Cause or coincidence?
-
Herbal supplements: Widely used, poorly understood.
-
High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial.
-
High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.
-
Hydroxychloroquine-induced hyperpigmentation: the staining pattern.
-
Hyperhidrosis in social anxiety disorder.
-
Hyperreactive platelet phenotypes: relationship to altered serotonin transporter number, transport kinetics and intrinsic response to adrenergic co-stimulation.
-
Hypothesis: antiplatelet effects of selective serotonin reuptake inhibitors cause clinical benefits on cardiovascular disease and increase risks of bleeding.
-
Identifying serotonergic mechanisms underlying the corticolimbic response to threat in humans.
-
Impact of depressive symptoms on the treatment of generalized social anxiety disorder.
-
Impact of sleep complaints and depression outcomes among participants in the standard medical intervention and long-term exercise study of exercise and pharmacotherapy for depression.
-
Improvement of anger at one week predicts the effects of sertraline and placebo in PTSD.
-
Increased ventromedial prefrontal cortex activity and connectivity predict poor sertraline treatment outcome in late-life depression.
-
Inflammation Markers and Major Depressive Disorder in Patients With Chronic Heart Failure: Results From the Sertraline Against Depression and Heart Disease in Chronic Heart Failure Study.
-
Insight and treatment outcome in obsessive-compulsive disorder.
-
Kava in generalized anxiety disorder: three placebo-controlled trials.
-
Long-lasting delayed hyperalgesia after subchronic swim stress.
-
Long-term treatment and prevention of posttraumatic stress disorder.
-
Management of Menopausal Symptoms for Women Who Are at High Risk of Thrombosis.
-
Marked differences in antidepressant use by race in an elderly community sample: 1986-1996.
-
Mediators of change in the Child/Adolescent Anxiety Multimodal Treatment Study.
-
Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients.
-
Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics.
-
Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients.
-
Methylene blue-induced serotonin syndrome after left ventricular assist device implantation: A case report and literature review.
-
Milnacipran: beyond a role of antidepressant.
-
Models of dopaminergic and serotonergic signaling.
-
Multi-informant Expectancies and Treatment Outcomes for Anxiety in Youth.
-
Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder.
-
Multidimensional effects of sertraline in social anxiety disorder.
-
Neural control of the urethra and development of pharmacotherapy for stress urinary incontinence.
-
New drugs for old folks: the evidence-based argument for newer antidepressants.
-
Off-label applications for SSRIs.
-
Off-label uses for selective serotonin reuptake inhibitors.
-
Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions.
-
Olanzapine increases allopregnanolone in the rat cerebral cortex.
-
Onset of activity and time to response on individual CAPS-SX17 items in patients treated for post-traumatic stress disorder with venlafaxine ER: a pooled analysis.
-
Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients.
-
Outcome at 6 months for 50 adolescents with major depression treated in a health maintenance organization.
-
Pain in depression: STAR*D study findings.
-
Panic disorder and social phobia: current treatments and new strategies.
-
Parental anxiety as a predictor of medication and CBT response for anxious youth.
-
Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy.
-
Paroxetine in the treatment of generalised anxiety disorder.
-
Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies.
-
Paroxetine: safety and tolerability issues.
-
Partial remission. A common outcome in older adults treated for major depression.
-
Patient beliefs predict response to paroxetine among primary care patients with dysthymia and minor depression.
-
Pediatric pain syndromes and management of pain in children and adolescents with rheumatic disease.
-
Perioperative Selective Serotonin Reuptake Inhibitor Use Is Associated With an Increased Risk of Transfusion in Total Hip and Knee Arthroplasty.
-
Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction.
-
Pharmacologic treatment of acute and chronic stress following trauma: 2006.
-
Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo.
-
Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway.
-
Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology.
-
Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome.
-
Pharmacotherapy of social anxiety disorder.
-
Pharmacotherapy of social phobia.
-
Placebo Response in Pediatric Anxiety Disorders: Results from the Child/Adolescent Anxiety Multimodal Study.
-
Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder.
-
Platelet aggregation and mental stress induced myocardial ischemia: Results from the Responses of Myocardial Ischemia to Escitalopram Treatment (REMIT) study.
-
Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors.
-
Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy.
-
Post-traumatic stress disorder: an evaluation of existing pharmacotherapies and new strategies.
-
Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS).
-
Predictors and moderators of treatment outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I).
-
Predictors and moderators of treatment response in childhood anxiety disorders: results from the CAMS trial.
-
Predictors associated with improved cognitive-behavioral therapy outcome in pediatric obsessive-compulsive disorder.
-
Predictors of antidepressant use among older adults: have they changed over time?
-
Predictors of nonresponse to treatment in primary care patients with dysthymia.
-
Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept.
-
Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept.
-
Prevalence of depression and its treatment in an elderly population: the Cache County study.
-
Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting.
-
Programming of brainstem serotonin transporter development by prenatal glucocorticoids.
-
Psychopharmacologic treatment of children and adolescents with anxiety disorders.
-
Psychosocial treatment within sex by ethnicity subgroups in the Enhancing Recovery in Coronary Heart Disease clinical trial.
-
QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: a case report and review of the literature.
-
Quality of life in geriatric depression: a comparison of remitters, partial responders, and nonresponders.
-
Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin.
-
Recent advances in the understanding and treatment of anxiety disorders. Resilience: determinants, measurement, and treatment responsiveness.
-
Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.
-
Reducing Suicidal Ideation Through Insomnia Treatment (REST-IT): A Randomized Clinical Trial.
-
Relapse of depression after electroconvulsive therapy.
-
Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression.
-
Remission after acute treatment in children and adolescents with anxiety disorders: findings from the CAMS.
-
Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes.
-
Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS).
-
Research knowledge among the participants in the Treatment for Adolescents With Depression Study (TADS).
-
Resolution of fear of flying with fluoxetine treatment.
-
Responses of mental stress-induced myocardial ischemia to escitalopram treatment: background, design, and method for the Responses of Mental Stress Induced Myocardial Ischemia to Escitalopram Treatment trial.
-
Results From the Child/Adolescent Anxiety Multimodal Extended Long-Term Study (CAMELS): Primary Anxiety Outcomes.
-
Results from the Child/Adolescent Anxiety Multimodal Longitudinal Study (CAMELS): Functional outcomes.
-
Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors.
-
Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity.
-
SSRI Augmentation by 5-Hydroxytryptophan Slow Release: Mouse Pharmacodynamic Proof of Concept.
-
SSRI/SNRI Therapy is Associated With a Higher Risk of Gastrointestinal Bleeding in LVAD Patients.
-
Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder.
-
Safety of selective serotonin reuptake inhibitor use prior to coronary artery bypass grafting.
-
Secondary outcomes from the pediatric obsessive compulsive disorder treatment study II.
-
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial.
-
Selective Serotonin Reuptake Inhibitors and Intracerebral Hemorrhage Risk and Outcome.
-
Selective serotonin reuptake inhibitors for fibromyalgia syndrome.
-
Selective serotonin reuptake inhibitors for the treatment of irritable bowel syndrome.
-
Selective serotonin reuptake inhibitors in post-traumatic stress disorder.
-
Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin.
-
Serotonergic modulation of bladder afferent pathways.
-
Sertraline and the Cheshire cat in geriatric depression.
-
Sertraline attenuates hyperphagia in rats following nicotine withdrawal.
-
Sertraline for treatment of depression in acute coronary syndromes.
-
Sertraline treatment of major depression in patients with acute MI or unstable angina.
-
Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease?
-
Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
-
Sleep-Related Problems and the Effects of Anxiety Treatment in Children and Adolescents.
-
Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept.
-
Social phobia: issues in assessment and management.
-
Somatic complaints in anxious youth.
-
Status of minor depression or dysthymia in primary care following a randomized controlled treatment.
-
Still Struggling: characteristics of youth with OCD who are partial responders to medication treatment.
-
Study refusal and exclusion from a randomized treatment study of generalized social phobia.
-
Suicidal events in the Treatment for Adolescents With Depression Study (TADS).
-
Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial.
-
TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.
-
Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs).
-
Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder.
-
The 5-HT deficiency theory of depression: perspectives from a naturalistic 5-HT deficiency model, the tryptophan hydroxylase 2Arg439His knockin mouse.
-
The Effects of Youth Anxiety Treatment on School Impairment: Differential Outcomes Across CBT, Sertraline, and their Combination.
-
The Impact of Treatment Expectations on Exposure Process and Treatment Outcome in Childhood Anxiety Disorders.
-
The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.
-
The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up.
-
The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks.
-
The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety.
-
The effects of congenital brain serotonin deficiency on responses to chronic fluoxetine.
-
The feasibility of a randomised, placebo-controlled clinical trial of homeopathic treatment of depression in general practice.
-
The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse.
-
The selective serotonin reuptake inhibitor citalopram induces the storage of serotonin in catecholaminergic terminals.
-
The therapeutic relationship in cognitive-behavioral therapy and pharmacotherapy for anxious youth.
-
Therapy for chemotherapy-induced peripheral neuropathy--in reply.
-
Therapy for mental stress-induced myocardial ischemia--reply.
-
Tic-related obsessive-compulsive disorder (OCD): phenomenology and treatment outcome in the Pediatric OCD Treatment Study II.
-
Tics Moderate Sertraline, but Not Cognitive-Behavior Therapy Response in Pediatric Obsessive-Compulsive Disorder Patients Who Do Not Respond to Cognitive-Behavior Therapy.
-
Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release.
-
Tolerability of fluoxetine in posttraumatic stress disorder.
-
Trajectories of Functioning Into Emerging Adulthood Following Treatment for Adolescent Depression.
-
Trauma, resilience and saliostasis: effects of treatment in post-traumatic stress disorder.
-
Treating Pediatric Anxiety: Initial Use of SSRIs and Other Antianxiety Prescription Medications.
-
Treatment considerations for patients with neuropathic pain and other medical comorbidities.
-
Treatment for Adolescents With Depression Study (TADS): rationale, design, and methods.
-
Treatment of anxiety in patients with coronary heart disease: Rationale and design of the UNderstanding the benefits of exercise and escitalopram in anxious patients WIth coroNary heart Disease (UNWIND) randomized clinical trial.
-
Treatment of mild depression in elderly patients.
-
Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial.
-
Treatment of posttraumatic stress disorder: the impact of paroxetine.
-
Treatment of social anxiety disorder with citalopram.
-
Treatment outcome and outcome associations in children with pervasive developmental disorders treated with selective serotonin reuptake inhibitors: a chart review.
-
Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study.
-
Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design.
-
Vintage treatments for PTSD: a reconsideration of tricyclic drugs.
-
Zolpidem for persistent insomnia in SSRI-treated depressed patients.
-
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.
-
[A new quality of the therapy of anxiety and depression--escitalopram].
-
fMRI tracks reductions in repetitive behaviors in autism: two case studies.
-
Keywords of People